First Tracks Biotherapeutics: Small Study Sparks Big Hopes

First Tracks Biotherapeutics is a US biotechnology company that develops antibodies for the treatment of autoimmune and inflammatory diseases. The company, based in San Diego, was formed through the spin-off from AnaptysBio and has been independently listed on Nasdaq since April 2026. The focus is on the drug candidate ANB033, which is being developed for celiac disease and a chronic inflammatory condition of the esophagus. The antibody is intended to specifically influence immune system signaling pathways, thereby reducing disease-triggering inflammation....